Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psoriasi...
Tallennettuna:
Päätekijät: | , , , , , , , , , , |
---|---|
Aineistotyyppi: | Kirja |
Julkaistu: |
PAGEPress Publications,
2022-10-01T00:00:00Z.
|
Aiheet: | |
Linkit: | Connect to this object online. |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
Hyllypaikka: |
A1234.567 |
---|---|
Nide 1 | Saatavissa |